METHOD OF INHIBITING REPLICATION OF HYPERPROLIFERATIVE CELLS

Abstract: This invention relates to methods for converting a pathologic hyperproliferative human cell to its non-malignant phenotype. The method comprises introducing into the cell a nucleic acid encoding a polypeptide having adenovirus E1A activity and growing the cellunder conditions such that the polypeptide is produced. This invention also relates to a method of converting a population of pathologic hyperproliferative cells in a subject to a non-hyperproliferative state by expressing, in some but not all of the hyperproliferative cells, an isolated nucleic acid sequence encoding a polypeptide having adenovirus E1A activity. In a further aspect, the invention relates to promoting differentiation of pathologically hyperproliferative cells.

Description: METHOD OF INHIBITING REPLICATION OF HYPERPROLIFERATIVE CELLS The present invention was made with support in part from a National Institutes of Health Grant 7-R29- GM44573-03 and an Institutional Support Grant Account No. 1-17071-6460. The United States Government may have certain rights in the invention. BACKGROUND OF THE INVENTION Adenovirus is a large DNA virus whose natural host is human cells. Virtually every adult has been infected with adenovirus at some time, the major effect being cold-like symptoms. Adenovirus is referred to as a "DNA tumor virus" purely because of its oncogenic effect in rodents. Expression of the adenovirus genome occurs in two stages. First, the early gene products are expressed which encode the E1A and E1B genes. These products are necessary for expression of the late gene products. Late gene products encode proteins necessary for replication as well as the viral structural proteins. The proteins encoded by the E1A gene of adenovirus have been studied primarily from two points of view. First, the 243 amino acid and 289 amino acid forms of E1A (arising from alternative splicing of the precursor RNA such that the 243 amino acid protein is a subset of the 289 amino acid protein) are both transcriptional regulatory proteins, J. Flint, T. Shenk, Ann. Rev. Gen. 23:141-161 (1989). Secondly, these proteins facilitate the oncogenic transformation of certain rodent cells by other oncogenes, H.E. Ruley, Nature 304:602-606 (1983), and, as such ElA is generally classified as an oncogene. The interactions of ElA proteins with various defined cellular proteins are believed to mediate its oncogenic effects in rodent cells. J.M. Howe, et al., Proc. Natl. Acad. Sci. 87:5883-5887 (1990) . In human cells, ElA does not appear to cooperate with other oncogenes to transform cell lines, however, mild tumorigenic effects have been reported in only two instances. For example, embryonic kidney, F. Graham, J. Smiley, . Russell, R. Nairn, J. Gen. Virol. 36:59-72 (1977), and embryonic retinoblast cell lines, P.J. Byrd, K.W. Brown, P.H. Gallimore, Nature 298:67-71 (1982), stably expressing ElA are weakly tumorigenic when injected into mice. Moreover, these transformants arise very rarely after cotransfection of ElA with another oncogene. The normal and transformed phenotypes of a cell are thought to be maintained by a balance of activities encoded by oncogenes and antioncogenes (tumor suppressor genes). The absence of functional tumor suppressor gene products contributes to carcinogenesis. Conversely, replacement or overexpression of these products promises to be useful in controlling tumor cell growth. Only a limited number of tumor suppressor genes have been characterized at present, notably, retinoblastoma protein, Huang et al.. Science 24:1563-1566 (1988), and p53, Chen et al.. Science 250:1566-1570 (1990). However, when reintroduced into tumor cells, both of these gene products simply kill the cells. Two reports in the literature claim tumor suppression effects of ElA, but both of these effects arose from epiphenomena not related to the growth controlling effects of ElA expression. Rat sarcoma cells stably transfected with ElA are less tumorigenic in nude rats than their untransfected counterparts (T.A. Walker, B.A. Wilson, A.M. Lewis, J.L. Cook, Proc. Natl. Acad. Sci.. 88:6491-6495 (1991). Decreased tumorigenicity of ElA-expressing cells resulted from senβitization of these cells to cytolysis by natural killer cells and these cells were still tumorigenic in nude mice. The second report (D. Yu, K. Scorsone, M.C. Huang Molec. Cell Biol. 11:1745-1750 (1991) showed that ElA prevented an oncogene known as neu from transforming the mouse cell line 3T3. ElA accomplished this solely by inhibiting the expression of neu at the transcriptional level. 3T3 cells transfected with a chimeric neu gene that utilized an ElA-resistant gene promoter were still transformed by neu even in the presence of ElA. The use of ElA to suppress tumor proliferation in the manner implied by the observations above would require ElA expression in all of the cells in the tumor. This requirement poses extreme practical limitations on the use of tumor suppressor genes for therapy since the technology does not exist to introduce a desired gene into 100% of the cell population. In light of these drawbacks, strategies for inhibiting the uncontrolled replication of hyperproliferative cells using tumor suppressor genes have not yet emerged. Thus, there exists a need to regulate hyperproliferative cell populations through small subpopulations of cells endowed with the ability to dominantly influence their growth. The present invention satisfies this need and provides related advantages as well. SUMMARY OF THE INVENTION This invention relates to methods for converting a pathologic hyperproliferative human cell to its non- malignant phenotype. This effect occurs even in cells transformed by oncogenes other than neu. The method comprises introducing into a cell a nucleic acid encoding a polypeptide having adenovirus ElA activity and growing the cell under conditions such that the polypeptide is produced. This invention also relates to a method of inhibiting the growth of a population of pathologic hyperproliferative cells in a subject by expressing, in some but not all of the hyperproliferative cells, an isolated nucleic acid sequence encoding a polypeptide having adenovirus ElA activity. In a further aspect, the invention relates to promoting differentiation of pathologically hyperproliferative cells. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Demonstration that ElA can be stably expressed in transfected tumor cells. Immunoprecipitation of ElA proteins from stably transfected and parental cell lines. [35S]Methionine-labeled proteins from ElA- expressing clones derived from HT1080 cells (lanes 1-5), HeLa cells (lanes 6-8), or A2058 cells (lanes 9-11) were immunoprecipitated with anti-ElA antibodies (E) or control antibodies (C) . Lanes: 1-5, HT1080, p2AHT2a, plAneo3, plAneol5, and plAneolδ, respectively: 6-8, HeLa, Medglδ, and Medg28, respectively: 9-11, A2058, 1A58C8-1, and lA58cll-l, respectively. The bands corresponding to ElA protein species are bracketed. Figure 2. Demonstration that ElA expressing cells are converted into a flat, contact-inhibited morphology. Phase-contrast micrographs of parental (top row) , neomycin-resiεtance transfected (middle row) , and ElA-expressing (bottom row) human tumor cells. Bottom row, photomicrographs of HTl080neo r and ElA-expressing HT1080 soft agarose colonies. Figure 3. Demonstration that ElA expression causes loss of anchorage-independent growth (soft agarose colony formation) in transfected tumor cells. Soft agarose colony formation assays of parental neomycin-resistance transfected, and ElA-expressing human tumor cells. Figure 4. Demonstration that ElA reduces tumorigenicity of human tumor cells. Tumorigenicity of parental tumor cells (HT1080, A2058, and HeLa) and ElA derivatives in nude mice. Figure 5. DNA sequence of ElA coding sequences (cDNA) (SEQ ID NOS. 1-4). Bottom line: 243 amino acid sequence (SEQ ID NOS. 1 and 2). Top line: 289 amino acid sequence (SEQ ID NOS. 3 and 4). Figure 6. Structure of a reverse-transforming retrovirus construct. The 243 amino acid form of ElA (12S cDNA) was cut at adenovirus map position 610 with BstXl and the 5 ' end was reconstructed with a double-stranded oligonucleotide, thus removing all ElA 5' noncoding sequences. The Hindlll end of this oligonucleotide was made blunt ended and the 3' end of ElA was cut with Hpal (map position 1575) to remove the polyA addition site. The resulting ElA sequence was subcloned into the retrovirus vector LNSX (described in Miller and Rosman, Biotechniques 7:980-990 (1989). Retroviruses were then packaged as described in the text. DETAILED DESCRIPTION OF THE INVENTION The present invention results from the observation that the adenovirus ElA gene unexpectedly influences the phenotype of human tumor cells so as to restore their contact inhibitory properties and promote their differentiation. This effect occurs even in cells transformed by oncogenes other than neu. Stable expression of the adenovirus 5 ElA gene reduces anchorage-independent growth and tumorigenic potential, promotes reorganization, induces flat morphology, and restores contact inhibition in human tumor cell lines. By these criteria, ElA functions as a tumor suppressor gene in this human context. The apparent paradox accorded by the observations of the ability of ElA to transform rodent cells in cooperation with other oncogenes suggests that ElA may be the prototype of a class of growth-regulatory proteins having context- specific transforming and antioncogenic activities. These unexpected observations provide the basis for this invention, which in one embodiment provides a method for reverse-transforming pathologic hyperproliferative mammalian cells. The cells are contacted with an effective amount of nucleic acid encoding a polypeptide having ElA activity under conditions such that the nucleic acid is introduced into the cell. The cell is then grown under conditions such that the polypeptide is expressed. The method may be practiced in vitro or iri vivo. Provided by this invention is a method for reversing the transformed phenotype of hyperproliferative cells located in pathological tissue by transducing with, for example, retroviral vectors, isolated nucleic acids having ElA activity. Transducing vectors can be introduced by direct injection or other suitable application. Such reverse-transformed cells will arrest growth of neighboring, non-transduced cells. Alternatively, provided by this invention is a method of reverse-transforming a population of pathologic hyperproliferative cells in a subject which comprises obtaining a suitable sample of cells from the subject, contacting the cells with a suitable retroviral vector containing nucleic acid encoding a polypeptide having ElA activity for a time period for transfection of the nucleic acid into the cell. These cells are then grown under suitable conditions such that the nucleic acid is expressed. The actively expressing cells are then reinfused into the subject. As used herein, the term "hyperproliferative," as it relates to cells, includes but is not limited to those cells having the capacity for autonomous growth, i.e., existing and reproducing independently of normal regulatory mechanisms. Hyperproliferative diseases may be categorized as pathogenic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state. "Pathologic hyperproliferative" cells occur in disease states characterized by malignant tumor growth including but not limited to breast cancer, sarcomas and other neoplasms, bladder cancer, colon cancer, lung cancer, various leukemias and lymphomas. In addition, the term can be applied to such conditions as thyroid hyperplasia and benign prostatic hypertrophy. Examples of non-pathologic hyperproliferative cells are found, for example, in embryonic tissue, in mammary ductal epithelial cells during development of lactation and also in cells associated with wound repair. Pathologic hyperproliferative cells characteristically exhibit loss of contact inhibition and a decline in their ability to selectively adhere which implies a change in the surface properties of the cell and a further breakdown in intercellular communication. The sequence of ElA is provided in Figure 5 (SEQ ID NOS. 1-4). The ElA gene product has the capacity, when expressed in a malignant cell to convert the phenotype such that the resulting cell is able to inhibit the growth of neighboring tumor cells. Such capacity is herein termed ElA activity. The invention is intended to ElA, its functional subunits and fragments and modifications to the native sequence which retain ElA activity. As used herein, the term "nucleic acid" means DNA, RNA or cDNA. A "polypeptide having ElA activity" encompasses any amino acid sequence having the biological activity of the adenovirus ElA gene product. In the preferred embodiment of this invention, this amino acid sequence is the 243 amino acid polypeptide product of the adenovirus ElA gene, as provided in Figure 5 (SEQ ID NOS. 1 and 2). Functional equivalents of the 243 amino acid polypeptide are polypeptides that specifically can also effect promotion of contact inhibition as provided herein. As used herein, the term "introducing" encompasses any method of inserting an exogenous nucleic acid molecule into a cell and includes, but is not limited to transduction, transfection, microinjection and viral infection of host cells. Methods of carrying out these procedures are well known to those of skill in the art. In the preferred embodiment of this invention, the nucleic acid is introduced into the cell by contacting a cell with a retroviral vector containing the nucleic acid under conditions such that the nucleic acid is inserted into the cell. In the most preferred embodiment of this invention, the virus is a replication-incompetent retrovirus. A replication-incompetent retrovirus is defined as a virus not having the ability to produce viral proteins, precluding spread of the vector in the infected host cells. Examples of such vectors useful for the practice of this invention are well known and readily available to those of skill in the art. Isolated nucleic acids useful in this invention are those that encode a polypeptide functionally equivalent to a polypeptide encoded by the ElA region of the adenovirus genome. In the preferred embodiment of this invention, the isolated nucleic acid is the adenovirus ElA region. This region is defined by those of skill in the art to be from nucleotide 560 to nucleotide 1542. This invention also provides a novel form of cancer therapy. Previously, anti-cancer genes or drugs targeted to kill tumor cells were effective in eradicating tumors only if 100% of the cells are exposed to the drug and forced to express the gene. This consistent exposure is seldom, if ever, achieved ji vivo. Malignant cells transfected to express the isolated nucleic acids of this invention can dominantly prevent the growth of neighboring tumor cells. Thus, by converting a small fraction of the malignant cells, the tumor can be effectively eradicated or inhibited. The following examples are intended to illustrate but not limit the invention. EXAMPLE I Material and Methods Stable ElA-expressing cell lines from A2058 melanoma and HT1080 fibrosarcoma cells were constructed using the plasmid plAneo as described in Frisch et al., Oncoqene 5:75-83 (1990), incorporated herein by reference. ElA-expressing HeLa cells, as described in Brunet and Berk, Mol. Cell. Biol. 8:4799-4807 (1988), incorporated herein by reference, were obtained from L. Brunet and A. Berk (University of California, Los Angeles). Cells labeled HTl080neo r and A2058neo r resulted from transfection with Bluescript plasmid (Stratagene, La Jolla, CA) containing ' the simian virus 40 early enhancer-promoted aph gene (encoding resistance to G418). Cells were plated at 4 x 10 4 (A2058 and derivatives), 3 x 10 4 (HeLa and derivatives), or 2 x 10 5 (HT1080 and derivatives) cells per 60-mm plate as described in Freedman et al., Proc. Natl. Acad. Sci. USA 72:4435-4439 (1972) and Tucker et al.. Cancer Res. 37:1571-1579 (1977), which are incorporated herein by reference, and stained, after a 14- to 17-day incubation with p- iodonitrotetrazolium violet (0.5 mg/ml) for 16 h. Cells were injected into 4- to 5-week old athymic nude mice (Harian-Sprague-Dawley) in 0.25 ml of phosphate- buffered saline at the indicated cell number. Nine mice were injected per cell line, and tumors were dissected at the indicated incubation times. Confluent cultures of cell lines (containing 2 x 10 6 cells) were labeled for 5 hours in 35-mm wells with 0.4 mCi (1 Ci = 37 GBq) of [ 35 S] methionine (Tran 35 S-label, ICN) in methionine-free Dulbecco's modified Eagle's medium containing 5% (vol/vol) dialyzed fetal calf serum. Cells were washed twice in phosphate-buffered saline and scraped into 1.0 ml of RIPA-1 [50 mM Tris-HCl, pH 7.5/0.1% Nonidet P-40/250mM NaCl/aprotinin (10 μg/ml) leupeptin (5 μg/ml)l mM phenylmethylsulfonyl fluoride/5 mM EDTA/soybean trypsin inhibitor (10 μg/ml)]. After addition of bovine serum albumin to 0.5 mg/ml, lysates were preabsorbed with 100 μl of a 50% (wt/vol) protein A-Sepharose (Pharmacia) slurry (prepared in RIPA-1 containing bovine serum albumin at 0.5 mg/ml) by mixing at 4°C for 30 min and centrifuging for 10 min at 14,000 rpm in an Eppendorf microcentrifuge and 0.5- ml samples were then incubated with 1.5 μg of anti-ElA monoclonal antibody M73 (12) or control antibody [anti-fos Ab-1 (Oncogene Sciences, Mineola, NY)] for 2 h at 0°C. Then 25 μl of 50% protein A-Sepharose slurry was added and the tubes were mixed for 20 min at 4°C followed by a 2-min centrifugation and five 0.5-ml washes with RIPA-1. Pellets were then resuspended in 60 μl of sample buffer and analyzed with SDS/PAGE. EXAMPLE II Reverse Transformation of Malignant Cells The expression of the ElA gene was documented at the RNA level by Northern blot analysis as described in Frisch et al., Oncogene 5:75-83 (1990) and Brunet and Berk, Mol. Cell. Biol. 8:4799-4807 (1988), which are incorporated herein by reference and, in the present study, protein expression was documented by immunoprecipitation with ElA- specific monoclonal antibodies (Figure 1). Multiple species of ElA protein were detected on the gel. In each case, the ElA-transfected cells are relatively flat and "epithelioid" compared with the respective parental cell lines or lines transfected with the aph gene alone (Figure 2A) . These morphologic changes are consistent with the widely reported observation that transformed cells tend to be more refractile and less substrate-attached than normal cells as described in Edelman and Yahara, Proc. Natl. Acad. Sci. USA 73:2047-2051 (1976). The altered morphology was observed at the time the colonies were first identified on the G418-selection plates, suggesting that secondary stochastic changes in the genome are not required for induction of the altered phenotype. TABLE 1 Tumorigenicity of parental tumor cells (HT1080, A2058, and HeLa) and ElA derivatives in nude mice Cells Average injected, Incubation tumor mass, Cell line no. time,days g SD The tumorigenicity of cells in vivo generally correlated with their ability to form anchorage-independent colonies (Shin et al., Proc. Natl. Acad. Sci. USA 72:4435- 4439 (1972) and Tucker et al.. Cancer Res. 37:1571-1579 (1977), which are hereby incorporated by reference). To test for anchorage-independent growth, cell lines were plated in soft agarose at fixed cell number and monitored for colony formation. While the parental tumor cell lines formed colonies in soft agarose (=1% efficiency) , ElA- expressing clones derived from these cell lines failed to form colonies (Figure 3). In fact, microscopic examination revealed that the ElA-expressing clones failed even to initiate colony formation on soft agarose, ruling out a growth-rate effect. The colony-suppressed phenotype was never observed among 15 independent HT1080 clones that had been transfected with the aph gene alone and selected for G418 resistance; these results indicate that the soft agarose colony suppression was an effect of the ElA gene and not of the selection process. These observations demonstrate that ElA expression can convert the human tumor cells to a phenotype that is anchorage-dependent for growth. To test whether ElA expression rendered the human tumor cell lines non-tumorigenic in vivo , they were injected subcutaneously into nude athymic mice and monitored for tumor formation (Figure 4). The parental cell lines formed large tumors with incubation times of 15- 17 days. In contrast, the ElA-expressing A2058 and HT1080 cells produced undetectable or very small tumors. ElA only partially suppressed tumorigenicity in the HeLa cells (4- fold) , possibly because transcription from the glucocorticoid-dependent murine mammary tumor virus promoter, which was driving the ElA gene, was compromised in the subcutaneous environment. To further rule out the possibility that ElA simply slowed growth rates so as to render soft agar colonies and tumors undetectable at short time points, growth curves were constructed. ElA did not substantially affect the growth rate of subconfluent tumor cells. The possibility that the tumor suppression could have been augmented by the ability of ElA to sensitize certain cells to lysis by tumor necrosis factor α was also considered. This was, however, unlikely in that 51 Cr- labeled p2AHT2a cells gave only 18% more lysis than parental HT1080 cells in tumor necrosis factor α at 500 units/ml—a dose high enough to kill nearly 100% of sensitive rodent cells. This is the first time that the phenotypic effects of ElA in human cells have been described. The experiments reported here establish that ElA converts three diverse types of human tumor cells into a phenotypically non-transformed state. Paradoxically, a salient phenotypic effect of adenovirus ElA is collaboration with the ras oncogene to transform primary rodent cells. Since specific rodent cell types can turn out to be affected antioncogenically by ElA, it would be premature to ascribe this discrepancy to species differences only, especially since the effects of ElA expression in spontaneously transformed rodent cell lines have not been reported. EXAMPLE III Inhibition of Tumor Cell Growth By Contact Inhibition This example describes a method for inhibiting the uncontrolled replication of human tumor cells through contact inhibition with cells reverse transformed by ElA expression. Construction of ElA viral expression vectors was achieved by subcloning cDNAs encoding the 243 amino acid (SEQ ID NOS. 1 and 2) or 289 amino acid (SEQ ID NOS. 3 and 4) ElA proteins of adenovirus type 5 into the retroviral vectors: LNCX, LNSX. (For vector descriptions, see Miller and Rosman, Biotechniσues 7:980-990 (1989); details of plasmid constructions are given in the legend to Figure 6) . 10 μg of these plasmid DNAs were transfected as in Example 11 into the ecotropic packaging cell line gpE86 (maintained in hygromycin/mycophenolic acid selection medium) . At 48 h post transfection, unselected virus stocks were prepared by collecting conditioned media, clearing by centrifugation and freezing. These viral stocks were used to infect the amphotropic packaging cell line gpEaml2 (cells available from ATCC) in 35 mm wells by incubation for 12 h in DME/10% fetal calf serum media containing 4 μg/ml polybrene. At 24 h post-infection, cells were split at ratios between 1:100- 1:300, and infected cells were selected in 500 μg/ml G418 for 3 weeks. Virus-producing cell lines were expanded into 35 mm wells and conditioned media containing virus was prepared for each line. Virus stocks were prepared from producer cell lines containing either 243 amino acid ElA or 289 amino acid ElA, in the vectors LNCX and LNSX (which promote transcription using internal CMV or SV40 early enhancers, respectively) . These stocks were used to infect the human fibrosarcoma line HT1080 by incubating 0.4 ml of virus stock with a 35 mm well of HT1080 cells for 8 h in medium containing polybrene; infected cells were split at various ratios 24 h post-infection, and either G418-resistant clones or mixed populations of infected cells were analyzed further. The results were as follows. In cultures infected with some of the virus stocks, no morphologic change was observed compared with the uninfected controls. Western blotting demonstrated that these infected cultures were negative for ElA expression, possibly as a result of rearrangement of retroviral DNA sequences in the producer cell lines. With one of the virus stocks, encoding the 243 amino acid form of ElA in the LNSX vector (especially 4/LNSX8), essentially 100% of the cells were converted into a morphology closely resembling that of ElA-transfected cells (see Figure 2). Upon prolonged incubation, these cells maintained their epitheloid morphology and failed to grow beyond monolayer stage, suggesting contact inhibition of growth. These cells expressed an amount of ElA protein per cell comparable with the levels seen in calcium phosphate-transfected cell lines, but all of this ElA was the 243 amino acid form, as expected. With other virus stocks, a mixture of "transformed morphology" and "ElA morphology" clones was noted after G418 selection. Significantly, upon longer incubation, these cultures were found to eventually (2-3 weeks post-infection) convert into nearly 100% "ElA morphology"; i.e., epitheloid, contact-inhibited cells. The latter phenomenon indicates that cells expressing ElA contact-inhibit each other. They also contact-inhibit tumor cells. Consistant with this observation is that the tumor cells are incapable of "sending" contact inhibition signals as expected, but are capable of "receiving" and responding to them. These differential signaling responses eventually produce the outcome described in the preceding paragraph. Thus, contact inhibition can be achieved within an hyperproliferating cell population by expressing ElA in a fraction of the cells and not within the total population. The conceptual advance bearing important ramifications for cancer therapy is as follows. Genes or drugs targeted to kill tumor cells are effective in eradicating tumors only if 100% of the cells are exposed to the drug or forced to express the gene. This condition is seldom, if ever, satisfied in vivo. ElA-expressing cells can dominantly prevent the growth of neighboring tumor cells, so forcing a small fraction of the cells in a tumor to express ElA will to eradicate the tumor. Delivery of ElA by retroviral vectors will achieve this effect. ElA is unique among tumor suppressor genes presently characterized in preserving the viability of the cells into which it is introduced, and this property can be exploited to eradicate tumor growth. EXAMPLE IV Effect of ElA on Differentation A retrovirus bearing the wild-type 243 amino acid ElA gene was constructed as follows. The BstXI partial- Pstl fragment from the plasmidl2Swt (Moran et al., Mol. Cell. Biol. 6:3470-3480 (1986)) (containing adenovirus map positions 610-1835) was three-way ligated with a synthetic oligonucleotide containing adenovirus map positions 555-610 (with a synthetic 5' Hindlll end) and Bluescript which had been cut with Hindlll and Pstl. This generated a plasmid containing complete 243 aa coding sequence without any upstream sequences from adenovirus. A Hindlll-Hpal fragment (555-1575) from this plasmid, (which excluded 3' polyadenylation sequences from Ela) was then made blunt- ended with Klenow enzyme and subcloned into the Stul site of the retrovirus vector LNSX (Miller and Rosman, supra) , which is incorporated herein by reference. The packaging cell line gpE86 was transiently transfected with this plasmid, and the resulting virus stock used to infect the amphotropic packaging cell line gpEaml2. G418 (500 μg/ml)- resistant producer cell lines were screened by Western blotting for ability to confer ElA expression on infected HT1080 cells. H4, a homogeneous subclone of H88T1080 fibrosarcoma cells, were made to express the adenovirus-5 gene by infection with viral supernatant for 8 hours in growth medium containing 4 μg/ml polybrene. 24 hours after infection, cells were replated and selected for 2 to 3 weeks in 500 μg/ml G418. Colonies were picked, expanded and screened for Ela expression by Western blotting using the antibody M73 (Oncogene Science). Other tumor cell lines were made to express Ela in a similar manner. Phase contrast microscopy revealed that HT1080 cells (ATCC Accession No. CCL121), A2058 melanoma cells, Saos2 osteosarcoma cells and normal fibroblasts all adopted an epithelial-type morphology after introduction and expression of the Ela gene. Electron microscopy was performed on the Ela- expressing H4 cells and they were found to contain epithelial-specific junctional structures such as tight junctions and desmosomes. Immunofluorescence was also performed on acetone- fixed cells grown on glass coverslips. After reaction with the anti-desmoplakin antibody NW6 (K. Green, Northwestern University), cells were reacted with rhodamine-labelled anti-mouse antibody and examined in a Zeiss Axiovert fluorescence microscope. Structures labelled with the antibody that closely resembled the desmosomes of authentic epithelial cells were observed in the Ela-expressing derivatives of H4 cells but not in parental H4 cells. Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: LA JOLLA CANCER RESEARCH FOUNDATION (ii) TITLE OF INVENTION: METHOD OF INHIBITING REPLICATION OF HYPERPROLIFERATIVE CELLS (iii) NUMBER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: CAMPBELL AND FLORES (B) STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700 (C) CITY: SAN DIEGO (D) STATE: CALIFORNIA (E) COUNTRY: UNITED STATES (F) ZIP: 92122 (V) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 ( i) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 12-OCT-1992 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: PERKINS, SUSAN M. (B) REGISTRATION NUMBER: 36,405 (C) REFERENCE/DOCKET NUMBER: FP-LJ 9770 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 619-535-9001 (B) TELEFAX: 619-535-8949 (2) INFORMATION FOR SEQ ID Nθ:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1000 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join(10..423, 678..993) (D) OTHER INFORMATION: /note= "THIS PROTEIN IS THE PRODUCT OF ALTERNATIVE SPLICING OF THE PRECURSOR RNA SUCH THAT THE PROTEIN IN THIS FORM IS A SUBSET OF THE LARGER ElA PROTEIN AS SHOWN IN SEQ ID NOS. 3-4. (Xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l: GGACTGAAA ATG AGA CAT ATT ATC TGC CAC GGA GGT GTT ATT ACC GAA 48 Met Arg His lie lie Cys His Gly Gly Val ie Thr Glu 1 5 10 GAA ATG GCC GCC AGT CTT TTG GAC CAG CTG ATC GAA GAG GTA CTG GCT 96 Glu Met Ala Ala Ser Leu Leu Asp Gin Leu lie Glu Glu Val Leu Ala 15 20 25 GAT AAT CTT CCA CCT CCT AGC CAT TTT GAA CCA CCT ACC CTT CAC GAA 144 Asp Asn Leu Pro Pro Pro Ser His Phe Glu Pro Pro Thr Leu His Glu 30 35 40 45 CTG TAT GAT TTA GAC GTG ACG GCC CCC GAA GAT CCC AAC GAG GAG GCG 192 Leu Tyr Asp Leu Asp Val Thr Ala Pro Glu Asp Pro Asn Glu Glu Ala 50 55 60 GTT TCG CAG ATT TTT CCC GAC TCT GTA ATG TTG GCG GTG CAG GAA GGG 240 Val ser Gin lie Phe Pro Asp Ser Val Met Leu Ala Val Gin Glu Gly 65 70 75 ATT GAC TTA CTC ACT TTT CCG CCG GCG CCC GGT TCT CCG GAG CCG CCT 288 lie Asp Leu Leu Thr Phe Pro Pro Ala Pro Gly Ser Pro Glu Pro Pro 80 85 90 CAC CTT TCC CGG CAG CCC GAG CAG CCG GAG CAG AGA GCC TTG GGT CCG 336 His Leu Ser Arg Gin Pro Glu Gin Pro Glu Gin Arg Ala Leu Gly Pro 95 100 105 GTT TCT ATG CCA AAC CTT GTA CCG GAG GTG ATC GAT CTT ACC TGC CAC 384 Val Ser Met Pro Asn Leu Val Pro Glu Val lie Asp Leu Thr Cys His 110 115 120 125 GAG GCT GGC TTT CCA CCC AGT GAC GAC GAG GAT GAA GAG GGTGAGGAGT 433 Glu Ala Gly Phe Pro Pro Ser Asp Asp Glu Asp Glu Glu 130 135 TTGTGTTAGA TTATGTGGAG CACCCCGGGC ACGGTTGCAG GTCTTGTCAT TATCACCGGA 493 GGAATACGGG GGACCCAGAT ATTATGTGTT CGCTTTGCTA TATGAGGACC TGTGGCATGT 553 TTGTCTACAG TAAGTGAAAA TTATGGGCAG TGGGTGATAG AGTGGTGGGT TTGGTGTGGT 613 AATTTTTTTT TTAATTTTTA CAGTTTTGTG GTTTAAAGAA TTTTGTATTG TGATTTTTTT 673 AAAA GGT CCT GTG TCT GAA CCT GAG CCT GAG CCC GAG CCA GAA CCG GAG 722 Gly Pro val Ser Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu 140 145 150 CCT GCA AGA CCT ACC CGC CGT CCT AAA ATG GCG CCT GCT ATC CTG AGA 770 Pro Ala Arg Pro Thr Arg Arg Pro Lys Met Ala Pro Ala lie Leu Arg 155 160 165 CGC CCG ACA TCA CCT GTG TCT AGA GAA TGC AAT AGT AGT ACG GAT AGC 818 Arg Pro Thr Ser Pro Val Ser Arg Glu Cys Asn Ser Ser Thr Asp Ser 170 175 180 185 TGT GAC TCC GGT CCT TCT AAC ACA CCT CCT GAG ATA CAC CCG GTG GTC 866 Cys Asp Ser Gly Pro Ser Asn Thr Pro Pro Glu lie His Pro Val Val 190 195 200 CCG CTG TGC CCC ATT AAA CCA GTT GCC GTG AGA GTT GGT GGG CGT CGC 914 Pro Leu Cys Pro ie Lys Pro Val Ala Val Arg Val Gly Gly Arg Arg 205 210 215 CAG GCT GTG GAA TGT ATC GAG GAC TTG CTT AAC GAG CCT GGG CAA CCT 962 Gin Ala Val Glu Cys lie Glu Asp Leu Leu Asn Glu Pro Gly Gin Pro 220 225 230 TTG GAC TTG AGC TGT AAA CGC CCC AGG CCATAAGGTG T 1000 Leu Asp Leu Ser cys Lys Arg Pro Arg Pro 235 240 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Arg His lie lie Cys His Gly Gly Val lie Thr Glu Glu Met Ala 1 5 10 15 Ala Ser Leu Leu Asp Gin Leu lie Glu Glu Val Leu Ala Asp Asn Leu 20 25 30 Pro Pro Pro Ser His Phe Glu Pro Pro Thr Leu His Glu Leu Tyr Asp 35 40 45 Leu Asp Val Thr Ala Pro Glu Asp Pro Asn Glu Glu Ala Val Ser Gin 50 55 60 lie Phe Pro Asp Ser Val Met Leu Ala Val Gin Glu Gly lie Asp Leu 65 70 75 80 Leu Thr Phe Pro Pro Ala Pro Gly Ser Pro Glu Pro Pro His Leu Ser 85 90 95 Arg Gin Pro Glu Gin Pro Glu Gin Arg Ala Leu Gly Pro Val Ser Met 100 105 110 Pro Asn Leu Val Pro Glu Val lie Asp Leu Thr Cys His Glu Ala Gly 115 120 125 Phe Pro Pro Ser Asp Asp Glu Asp Glu Glu Gly Pro Val Ser Glu Pro 130 135 140 Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Ala Arg Pro Thr Arg Arg 145 150 155 160 Pro Lys Met Ala Pro Ala lie Leu Arg Arg Pro Thr Ser Pro Val Ser 165 170 175 Arg Glu cys Asn Ser Ser Thr Asp ser Cys Asp ser Gly Pro Ser Asn 180 185 190 Thr Pro Pro Glu lie His Pro Val Val Pro Leu Cys Pro lie Lys Pro 195 200 205 Val Ala Val Arg Val Gly Gly Arg Arg Gin Ala Val Glu Cys lie Glu 210 215 220 Asp Leu Leu Asn Glu Pro Gly Gin Pro Leu Asp Leu Ser Cys Lys Arg 225 230 235 240 Pro Arg Pro (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1000 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join(10..561, 678..993) (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GGACTGAAA ATG AGA CAT ATT ATC TGC CAC GGA GGT GTT ATT ACC GAA 48 Met Arg His lie He Cys His Gly Gly Val He Thr Glu 1 5 10 GAA ATG GCC GCC AGT CTT TTG GAC CAG CTG ATC GAA GAG GTA CTG GCT 96 Glu Met Ala Ala Ser Leu Leu Asp Gin Leu He Glu Glu Val Leu Ala 15 20 25 GAT AAT CTT CCA CCT CCT AGC CAT TTT GAA CCA CCT ACC CTT CAC GAA 144 Asp Asn Leu Pro Pro Pro Ser His Phe Glu Pro Pro Thr Leu His Glu 30 35 40 45 CTG TAT GAT TTA GAC GTG ACG GCC CCC GAA GAT CCC AAC GAG GAG GCG 192 Leu Tyr Asp Leu Asp Val Thr Ala Pro Glu Asp Pro Asn Glu Glu Ala 50 55 60 GTT TCG CAG ATT TTT CCC GAC TCT GTA ATG TTG GCG GTG CAG GAA GGG 240 Val ser Gin He Phe Pro Asp Ser Val Met Leu Ala Val Gin Glu Gly 65 70 75 ATT GAC TTA CTC ACT TTT CCG CCG GCG CCC GGT TCT CCG GAG CCG CCT 288 He Asp Leu Leu Thr Phe Pro Pro Ala Pro Gly Ser Pro Glu Pro Pro 80 85 90 CAC CTT TCC CGG CAG CCC GAG CAG CCG GAG CAG AGA GCC TTG GGT CCG 336 His Leu Ser Arg Gin Pro Glu Gin Pro Glu Gin Arg Ala Leu Gly Pro 95 100 105 GTT TCT ATG CCA AAC CTT GTA CCG GAG GTG ATC GAT CTT ACC TGC CAC 384 Val Ser Met Pro Asn Leu Val Pro Glu Val He Asp Leu Thr Cys His 110 115 120 125 GAG GCT GGC TTT CCA CCC AGT GAC GAC GAG GAT GAA GAG GGT GAG GAG 432 Glu Ala Gly Phe Pro Pro Ser Asp Asp Glu Asp Glu Glu Gly Glu Glu 130 135 140 TTT GTG TTA GAT TAT GTG GAG CAC CCC GGG CAC GGT TGC AGG TCT TGT 480 Phe Val Leu Asp Tyr Val Glu His Pro Gly His Gly Cys Arg Ser Cys 145 150 155 CAT TAT CAC CGG AGG AAT ACG GGG GAC CCA GAT ATT ATG TGT TCG CTT 528 His Tyr His Arg Arg Asn Thr Gly Asp Pro Asp He Met Cys Ser Leu 160 165 170 TGC TAT ATG AGG ACC TGT GGC ATG TTT GTC TAC AGTAAGTGAA AATTATGGGC 581 cys Tyr Met Arg Thr Cys Gly Met Phe Val Tyr 175 180 AGTGGGTGAT AGAGTGGTGG GTTTGGTGTG GTAATTTTTT TTTTAATTTT TACAGTTTTG 641 TGGTTTAAAG AATTTTGTAT TGTGATTTTT TTAAAA GGT CCT GTG TCT GAA CCT 695 Gly Pro Val Ser Glu Pro 185 190 GAG CCT GAG CCC GAG CCA GAA CCG GAG CCT GCA AGA CCT ACC CGC CGT 743 Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Ala Arg Pro Thr Arg Arg 195 200 205 CCT AAA ATG GCG CCT GCT ATC CTG AGA CGC CCG ACA TCA CCT GTG TCT 791 Pro Lys Met Ala Pro Ala He Leu Arg Arg Pro Thr Ser Pro Val Ser 210 215 220 AGA GAA TGC AAT AGT AGT ACG GAT AGC TGT GAC TCC GGT CCT TCT AAC 839 Arg Glu Cys Asn Ser Ser Thr Asp Ser cys Asp Ser Gly Pro Ser Asn 225 230 235 ACA CCT CCT GAG ATA CAC CCG GTG GTC CCG CTG TGC CCC ATT AAA CCA 887 Thr Pro Pro Glu He His Pro Val Val Pro Leu Cys Pro He Lys Pro 240 245 250 GTT GCC GTG AGA GTT GGT GGG CGT CGC CAG GCT GTG GAA TGT ATC GAG 935 Val Ala Val Arg Val Gly Gly Arg Arg Gin Ala Val Glu cys He Glu 255 260 265 270 GAC TTG CTT AAC GAG CCT GGG CAA CCT TTG GAC TTG AGC TGT AAA CGC 983 Asp Leu Leu Asn Glu Pro Gly Gin Pro Leu Asp Leu Ser cys Lys Arg 275 280 285 CCC AGG CCATAAGGTG T 1000 Pro Arg Pro (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 289 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Arg His He He Cys His Gly Gly Val He Thr Glu Glu Met Ala 1 5 10 15 Ala Ser Leu Leu Asp Gin Leu He Glu Glu Val Leu Ala Asp Asn Leu 20 25 30 Pro Pro Pro Ser His Phe Glu Pro Pro Thr Leu His Glu Leu Tyr Asp 35 40 45 Leu Asp Val Thr Ala Pro Glu Asp Pro Asn Glu Glu Ala Val Ser Gin 50 55 60 He Phe Pro Asp Ser Val Met Leu Ala Val Gin Glu Gly He Asp Leu 65 70 75 80 Leu Thr Phe Pro Pro Ala Pro Gly Ser Pro Glu Pro Pro His Leu Ser 85 90 95 Arg Gin Pro Glu Gin Pro Glu Gin Arg Ala Leu Gly Pro Val Ser Met 100 105 110 Pro Asn Leu Val Pro Glu Val He Asp Leu Thr cys His Glu Ala Gly 115 120 125 Phe Pro Pro Ser Asp Asp Glu Asp Glu Glu Gly Glu Glu Phe Val Leu 130 135 140 Asp Tyr Val Glu His Pro Gly His Gly Cys Arg Ser cys His Tyr His 145 150 155 160 Arg Arg Asn Thr Gly Asp Pro Asp He Met cys Ser Leu Cys Tyr Met 165 170 175 Arg Thr Cys Gly Met Phe Val Tyr Gly Pro Val Ser Glu Pro Glu Pro 180 185 190 Glu Pro Glu Pro Glu Pro Glu Pro Ala Arg Pro Thr Arg Arg Pro Lys 195 200 205 Met Ala Pro Ala He Leu Arg Arg Pro Thr Ser Pro Val Ser Arg Glu 210 215 220 Cys Asn Ser Ser Thr Asp ser cys Asp Ser Gly Pro Ser Asn Thr Pro 225 230 235 240 Pro Glu He His Pro Val val Pro Leu cys Pro He Lys Pro Val Ala 245 250 255 Val Arg Val Gly Gly Arg Arg Gin Ala Val Glu Cys He Glu Asp Leu 260 265 270 Leu Asn Glu Pro Gly Gin Pro Leu Asp Leu Ser Cys Lys Arg Pro Arg 275 280 285 Pro

Claims: I claim: 1. A method for restoring the contact inhibition properties of a pathologically hyperproliferative human cell, comprising contacting said hyperproliferative cell with nucleic acid encoding a polypeptide having ElA activity under conditions such that said nucleic acid is introduced and said polypeptide is expressed in said pathologically hyperproliferative cell. 2. The method of claim 1, wherein the isolated nucleic acid encodes adenovirus ElA polypeptide. 3. The method of claim 1, wherein the contacting is effected in vitro. 4. The method of claim 1, wherein the contacting is effected in vivo. 5. The method of claim 1, wherein the pathologic hyperproliferative cell is a malignant cell. 6. The method of claim 1, wherein the isolated nucleic acid is introduced into the cell by contacting the cell with a suitable retroviral vector containing the isolated nucleic acid sequence. 7. A method for promoting the differentiation of a pathologically hyperproliferative human cell comprising contacting said pathologically hyperproliferative cell with nucleic acid encoding a polypeptide having ElA activity under conditions such that said nucleic acid is introduced and said polypeptide is expressed in said pathologically hyperproliferative cell. 8. The method of claim 7, wherein the isolated nucleic acid encodes adenovirus ElA polypeptide. 9. The method of claim 7, wherein the contacting is effected in vitro. 10. The method of claim 7, wherein the contacting is effected in vivo. 11. The method of claim 7, wherein the pathologic hyperproliferative cell is a malignant cell. 12. The method of claim 7, wherein the isolated nucleic acid is introduced into the cell by contacting the cell with a suitable retroviral vector containing the isolated nucleic acid sequence. 13. A method for inhibiting growth of a clonal population of pathologically hyperproliferative human cells comprising the steps of: (a) contacting at least some of said pathologically hyperproliferative cells with nucleic acid encoding a polypeptide having ElA activity under conditions such that the nucleic acid is introduced into some, but not all, of said hyperproliferative cells to form converted cells; (b) allowing said converted cells to contact the non-converted cells such that the growth of the population of pathologically hyperproliferative cells is reduced through contact inhibition from said converted cells. 14. The method of claim 13, wherein said contacting step is performed in vivo. 15. The method of claim 13, wherein said contacting step is performed in vitro. 16. The method of claim 13, wherein said cloned population of pathologic hyperproliferative cells is a malignant tumor. 17. The method of claim 13, wherein the isolated nucleic acid is introduced into the cell by contacting the cell with a suitable retroviral vector containing the isolated nucleic acid sequence.

Inventors: FRISCH STEVEN M, FRISCH, STEVEN, M.
Applicants: JOLLA CANCER RES FOUND, LA JOLLA CANCER RESEARCH FOUNDATION
Application year: 1993
Main classification: C12Q1
IPC codes: A61K31, A61K38, A61K48, A61P35, C07H21, C07K14, C12N5, C12N15, C12Q1